ArticleVaccine2007
Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 80 citations in OpenAlex.
- An Overview of the Factors Related toVaccines · 2026Review
- Efficacy of LaAg Vaccine Associated with Saponin AgainstVaccines · 2025Article
- Application of the Sponge Model Implants in the Study of Vaccine Memory in Mice Previously Immunized with LBSap.Vaccines · 2024Article
- Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.Parasitology research · 2023Article
- Polymeric Delivery Systems as a Potential Vaccine against Visceral Leishmaniasis: Formulation Development and Immunogenicity.Vaccines · 2023Article
- The Use of an Adjuvant System Improves Innate and Adaptive Immune Response When Associated with aVaccines · 2023Article
- Article
- Article
- Nanoformulations withVaccines · 2022Article
- LBMPL Vaccine Therapy Induces Progressive Organization of the Spleen Microarchitecture, Improved Th1 Adaptative Immune Response and Control of Parasitism inPathogens (Basel, Switzerland) · 2022Article
- The History of Live AttenuatedPathogens (Basel, Switzerland) · 2022Review
- Vaccination in Leishmaniasis: A Review Article.Iranian biomedical journal · 2022Article
- Article
- Sphingomyelin liposome bearing wholeIranian journal of basic medical sciences · 2021Article
- Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis.Current research in immunology · 2021Article
- Phase I and II Clinical Trial Comparing the LBSap, LeishmuneVaccines · 2020Article
- Evaluation of Leishmanization UsingFrontiers in immunology · 2020Article
- Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis.Memorias do Instituto Oswaldo Cruz · 2020Article
- Performance of recombinant chimeric proteins in the serological diagnosis of Trypanosoma cruzi infection in dogs.PLoS neglected tropical diseases · 2019Article
- Peptide Vaccines for Leishmaniasis.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular and humoral immune responses of dogs to a candidate vaccine, composed of Leishmania braziliensis promastigote protein plus saponin as adjuvant, have been investigated as a pre-requisite to understanding the mechanisms of immunogenicity against canine visceral leishmaniasis (CVL). The candidate vaccine elicited strong antigenicity related to the increases of anti-Leishmania IgG isotypes, together with higher levels of lymphocytes, particularly of circulating CD8(+) T-lymphocytes and Leishmania chagasi antigen-specific CD8(+) T-lymphocytes. As indicated by the intense cell proliferation and increased nitric oxide production during in vitro stimulation by L. chagasi soluble antigens, the candidate vaccine elicited an immune activation status potentially compatible with effective control of the etiological agent of CVL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.